PANACEA BIOTEC LTD. SHARE PRICE [LIVE]

BSE: INE922B01023   NSE: PANACEABIO   SECTOR: Pharma

OPEN YOUR FREE DEMAT ACCOUNT AND START TRADING SEAMLESSLY
Already an existing customer? - Login Now!
NSE
130.50
Change:
BSE
130.50
Change:
NSE
BSE Click here to view BSE data
Loading, Please wait...
Error in Fetching Data, Please retry later.
No data available.
Open:
High:
Low:
MKT Cap:
52-wk High:
52-wk Low:
Prev close:
P/E:
Div yield:

Fundamental analysis

Quality
Valuation
0 250 500 750 1 000
Financial trend

What is not working for the company?

What is working for the company?

Stock
Sector
Sensex
Name Mar 21 Dec 20

Similar Stocks

Return Calculator

This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.

If I had made LUMPSUM investment of ₹ 1,00,000

in PANACEA BIOTEC LTD.

Months ago

My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %

PANACEABIO News

Frequently Asked Questions

What is the Share price of PANACEA BIOTEC LTD. (PANACEABIO)?

PANACEA BIOTEC LTD. (PANACEABIO) share price as of September 29, 2022, on NSE is Rs 130.50 (NSE) and Rs 130.50 (BSE) on BSE.

Can I buy PANACEA BIOTEC LTD. (PANACEABIO) shares?

Yes, You can buy PANACEA BIOTEC LTD. (PANACEABIO) shares by opening a Demat account with Angel One.

How do I buy PANACEA BIOTEC LTD. (PANACEABIO) from Angel One?

PANACEA BIOTEC LTD. (PANACEABIO) share can be brought through the following modes:
  1. Direct investment: You can buy PANACEA BIOTEC LTD. (PANACEABIO) shares by opening a Demat account with Angel One.
  2. Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to PANACEA BIOTEC LTD. (PANACEABIO) shares.

In which sector do PANACEA BIOTEC LTD. (PANACEABIO) belong?

PANACEA BIOTEC LTD. (PANACEABIO) belongs to Pharma.

About PANACEABIO

Today's live share price for PANACEA BIOTEC LTD. is NSE: ₹ 130.50, BSE: ₹ 130.50 with a current market capitalization of .

India's leading research-based health management company with established research, manufacturing and marketing capabilities are collectively known as Panacea Biotec Limited (PBL), which was incorporated on 2nd February 1984 under the name of Panacea Drug (P) Ltd. A second largest vaccine producer in India has the product portfolio of highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines. The Company has collaborations and tie-ups with leading national and international research organizations and corporations. PBL has ultra modern, state-of-art production facilities at Himachal Pradesh, Punjab & Delhi for manufacturing vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SAMCC and WHO-cGMP standards and it has four research and development centers. The Company also has 24 product patents, valid in more than 60 countries worldwide. The plant for vaccines production (Radicura Pharma) and pharmaceutical formulations plant (Panacea Drug P Ltd) at New Delhi were established during the year 1988 and 1989 respectively. In 1993, merger of Panacea Drugs (P) Ltd and Radicura Pharma gave the name Panacea Biotec Ltd. The Company made its Initial Public Offering (IPO) in the year of 1995 and also in the same year, PBL had formed state -of the- art Drug Delivery R&D centre at Lalru. In the year 1997, the company obtained its first product patent in several countries. PBL's Research & Development made a tie up with European MNC in the year 2001 and in 2002, an in-licensing agreement was made with Biotechnology Consortium of India for development & commercialization of Anthrax Vaccine. Also in the identical year of 2002, the company had commissioned Recombinant Vaccine production plant. During the year 2004, PBL made an in-licensing agreement with National Institute of Immunology, New Delhi, for Japanese Encephalitis Candidate Vaccine, marketing joint venture with Chiron (now Novartis) Vaccines, UK and also made collaboration with Cambridge Bio-stability, UK, for Thermo Stable Vaccines. After a year in 2005, an in-licensing agreement was prepared with National Institute of Health, USA for Hair Growth Hormone. During the year 2006, ultra modern Pharmaceuticals formulation facility at Baddi, Himachal Pradesh was goes live, which has WHO cGMP complaint. Landmark collaborations were made with The Netherlands Vaccine Institute (The Nederlands Vaccin Institute (NVI)) for manufacture & marketing of finished Inactivated Polio Vaccine (IPV) and a number of IPV based combination vaccines in India and across the globe. Collaboration was happened with PT.Bio Farma to manufacture & market Measles Vaccine. Also in the same year of 2006, the company had inaugurated its Biopharmaceutical R&D Centre at New Delhi and made collaboration with National Research Development Corporation (NRDC) for technology transfer of Foot and Mouth Vaccine. Vaccine Formulation Plant of the company was established at Baddi in the year 2007 and the research agreement was made with Punjab University to develop New Chemical Entities for Psychiatric Disorders. PBL forayed into Healthcare Delivery in the year 2008, made a collaboration to set-up 220 bed multi super-specialty hospital in NCR and also the company obtained a patent (Patent No. 7,371,412 B2) from US Patent & Trademark Office for the product Thank GodTM (Euphorbia Prostrata) for effective management of hemorrhoids & piles in the identical year of 2008.

Read more